

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Equality impact assessment – Scoping

Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379) [ID4062]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

At consultation, 1 consultee commented that a negative outcome will result in an inequality of access to treatment for patients above FVC 80% predicted in IPF as nintedanib is currently available for other progressive fibrotic diseases. However, this is not an equality or diversity issue which needed to be addressed in the scope.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

No issues relating to equality have been included in the scope.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No

- | |
|---|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes |
|---|

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379) [ID4062]

Issue date: April 2022

to the matrix been made?
No

Approved by Associate Director (name): Linda Landells

Date: 5 April 2022